Titan Pharmaceuticals Inc (TTNP) - Net Assets
Based on the latest financial reports, Titan Pharmaceuticals Inc (TTNP) has net assets worth $2.79 Million USD as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($3.05 Million) and total liabilities ($263.00K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check TTNP asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $2.79 Million |
| % of Total Assets | 91.38% |
| Annual Growth Rate | N/A |
| 5-Year Change | -30.92% |
| 10-Year Change | -65.09% |
| Growth Volatility | 182.92 |
Titan Pharmaceuticals Inc - Net Assets Trend (1995–2024)
This chart illustrates how Titan Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Also explore total assets of Titan Pharmaceuticals Inc for the complete picture of this company's asset base.
Annual Net Assets for Titan Pharmaceuticals Inc (1995–2024)
The table below shows the annual net assets of Titan Pharmaceuticals Inc from 1995 to 2024. For live valuation and market cap data, see TTNP stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $2.44 Million | -63.26% |
| 2023-12-31 | $6.64 Million | +387.31% |
| 2022-12-31 | $1.36 Million | -73.47% |
| 2021-12-31 | $5.14 Million | +45.47% |
| 2020-12-31 | $3.53 Million | +146.48% |
| 2019-12-31 | $1.43 Million | -79.02% |
| 2018-12-31 | $6.83 Million | +697.08% |
| 2017-12-31 | $857.00K | -93.50% |
| 2016-12-31 | $13.19 Million | +88.71% |
| 2015-12-31 | $6.99 Million | -18.82% |
| 2014-12-31 | $8.61 Million | +49.50% |
| 2013-12-31 | $5.76 Million | +124.90% |
| 2012-12-31 | $-23.13 Million | -15.19% |
| 2011-12-31 | $-20.08 Million | -231.72% |
| 2010-12-31 | $-6.05 Million | -2824.15% |
| 2009-12-31 | $-207.00K | -111.50% |
| 2008-12-31 | $1.80 Million | -93.23% |
| 2007-12-31 | $26.59 Million | +128.30% |
| 2006-12-31 | $11.65 Million | -29.85% |
| 2005-12-31 | $16.60 Million | -52.51% |
| 2004-12-31 | $34.95 Million | -23.46% |
| 2003-12-31 | $45.67 Million | -36.56% |
| 2002-12-31 | $71.98 Million | -28.99% |
| 2001-12-31 | $101.37 Million | -12.60% |
| 2000-12-31 | $115.98 Million | +154.90% |
| 1999-12-31 | $45.50 Million | +329.25% |
| 1998-12-31 | $10.60 Million | -42.39% |
| 1997-12-31 | $18.40 Million | +46.03% |
| 1996-12-31 | $12.60 Million | +373.91% |
| 1995-12-31 | $-4.60 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Titan Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 36533600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | 0.04% |
| Other Components | $398.98 Million | 16351.43% |
| Total Equity | $2.44 Million | 100.00% |
Titan Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Titan Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Alefarm Brewing AS
CO:ALEFRM
|
$6.13 Million |
|
Eo2 Société Anonyme
PA:ALEO2
|
$6.13 Million |
|
Nexgram Holdings Bhd
KLSE:0096
|
$6.14 Million |
|
East Side Games Group Inc
TO:EAGR
|
$6.14 Million |
|
Scandinavian Brake Systems A/S
CO:SBS
|
$6.12 Million |
|
Princess Private Equity Holding Ltd
LSE:PEYS
|
$6.12 Million |
|
enVVeno Medical Corp
NASDAQ:NVNO
|
$6.11 Million |
|
Papyrus Australia Ltd
AU:PPY
|
$6.11 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Titan Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 6,642,000 to 2,440,000, a change of -4,202,000 (-63.3%).
- Net loss of 4,706,000 reduced equity.
- Other factors increased equity by 504,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-4.71 Million | -192.87% |
| Other Changes | $504.00K | +20.66% |
| Total Change | $- | -63.26% |
Book Value vs Market Value Analysis
This analysis compares Titan Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.70x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1995-12-31 | $-758.96 | $4.61 | x |
| 1996-12-31 | $910.25 | $4.61 | x |
| 1997-12-31 | $1135.24 | $4.61 | x |
| 1998-12-31 | $709.97 | $4.61 | x |
| 1999-12-31 | $2722.13 | $4.61 | x |
| 2000-12-31 | $4438.78 | $4.61 | x |
| 2001-12-31 | $3592.26 | $4.61 | x |
| 2002-12-31 | $2533.67 | $4.61 | x |
| 2003-12-31 | $1576.06 | $4.61 | x |
| 2004-12-31 | $1063.60 | $4.61 | x |
| 2005-12-31 | $465.96 | $4.61 | x |
| 2006-12-31 | $271.78 | $4.61 | x |
| 2007-12-31 | $583.62 | $4.61 | x |
| 2008-12-31 | $30.57 | $4.61 | x |
| 2009-12-31 | $-24.52 | $4.61 | x |
| 2010-12-31 | $-101.14 | $4.61 | x |
| 2011-12-31 | $-329.16 | $4.61 | x |
| 2012-12-31 | $-344.27 | $4.61 | x |
| 2013-12-31 | $68.99 | $4.61 | x |
| 2014-12-31 | $90.86 | $4.61 | x |
| 2015-12-31 | $62.74 | $4.61 | x |
| 2016-12-31 | $110.66 | $4.61 | x |
| 2017-12-31 | $7.27 | $4.61 | x |
| 2018-12-31 | $36.03 | $4.61 | x |
| 2019-12-31 | $0.88 | $4.61 | x |
| 2020-12-31 | $1.77 | $4.61 | x |
| 2021-12-31 | $2.57 | $4.61 | x |
| 2022-12-31 | $2.03 | $4.61 | x |
| 2023-12-31 | $8.83 | $4.61 | x |
| 2024-12-31 | $2.71 | $4.61 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Titan Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -192.87%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.20x
- Recent ROE (-192.87%) is above the historical average (-230.67%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1995 | 0.00% | -11700.00% | 0.02x | 0.00x | $-11.12 Million |
| 1996 | -113.16% | -4300.00% | 0.02x | 1.44x | $-14.04 Million |
| 1997 | 3.49% | 3.43% | 0.68x | 1.49x | $-1.12 Million |
| 1998 | -112.77% | -10600.00% | 0.01x | 1.30x | $-11.54 Million |
| 1999 | -25.51% | -3766.67% | 0.01x | 1.07x | $-15.73 Million |
| 2000 | -16.37% | -999.36% | 0.02x | 1.03x | $-30.26 Million |
| 2001 | -17.44% | -381.98% | 0.04x | 1.07x | $-27.48 Million |
| 2002 | -39.84% | -974.48% | 0.04x | 1.07x | $-35.26 Million |
| 2003 | -67.28% | -33583.15% | 0.00x | 1.10x | $-34.33 Million |
| 2004 | -77.13% | -83883.87% | 0.00x | 1.15x | $-29.38 Million |
| 2005 | -146.24% | -25238.20% | 0.00x | 1.28x | $-24.00 Million |
| 2006 | -151.24% | -49178.13% | 0.00x | 1.45x | $-16.78 Million |
| 2007 | -69.62% | -73529.17% | 0.00x | 1.22x | $-20.18 Million |
| 2008 | -1412.78% | -36328.57% | 0.01x | 3.17x | $-25.61 Million |
| 2009 | 0.00% | -7450.63% | 0.02x | 0.00x | $-5.74 Million |
| 2010 | 0.00% | -67.71% | 2.12x | 0.00x | $-6.23 Million |
| 2011 | 0.00% | -373.72% | 0.40x | 0.00x | $-13.20 Million |
| 2012 | 0.00% | -213.29% | 0.29x | 0.00x | $-12.87 Million |
| 2013 | 168.59% | 92.65% | 0.57x | 3.20x | $9.13 Million |
| 2014 | -27.91% | -65.91% | 0.17x | 2.42x | $-3.26 Million |
| 2015 | -161.36% | -674.99% | 0.13x | 1.90x | $-11.98 Million |
| 2016 | 38.93% | 34.09% | 0.81x | 1.42x | $3.82 Million |
| 2017 | -1669.43% | -6654.42% | 0.02x | 10.39x | $-14.39 Million |
| 2018 | -132.09% | -152.65% | 0.42x | 2.06x | $-9.71 Million |
| 2019 | -1122.75% | -445.56% | 0.38x | 6.64x | $-16.23 Million |
| 2020 | -586.86% | -428.44% | 0.60x | 2.29x | $-21.08 Million |
| 2021 | -157.92% | -531.72% | 0.19x | 1.56x | $-8.63 Million |
| 2022 | -746.66% | -16961.67% | 0.01x | 2.98x | $-10.31 Million |
| 2023 | -83.85% | -556900.00% | 0.00x | 1.22x | $-6.23 Million |
| 2024 | -192.87% | 0.00% | 0.00x | 1.20x | $-4.95 Million |
Industry Comparison
This section compares Titan Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Titan Pharmaceuticals Inc (TTNP) | $2.79 Million | 0.00% | 0.09x | $6.13 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Titan Pharmaceuticals Inc
As of October 1, 2025, Titan Pharmaceuticals, Inc. was acquired by KE Sdn Bhd, in a reverse merger transaction. Titan Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development of therapeutics for the treatment of chronic diseases. Titan Pharmaceuticals, Inc. was founded in 1991 and is based in New York, New York.